RecruitingNCT07185503

Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

Studying Zygomycosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator: Sizhou Feng
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Intervention: liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole(drug)
Enrollment: 60 target
Eligibility: 18-65 years · All sexes
Timeline: 2025 – 2027

Study locations (9)

The Second Hospital of Dalian Medical University, Dalian, China
The First Affiliated Hospital of Harbin Medical University, Harbin, China
Shengjing Hospital of China Medical University, Shenyang, China
The First Affiliated Hospital of China Medical University, Shenyang, China
Tianjin First Central Hospital, Tianjin, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
Second Hospital of Tianjin Medical University, Tianjin, China
Tianjin Haihe Hospital, Tianjin, China
Tianjin Union Medical Center of Nankai University, Tianjin, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07185503 on ClinicalTrials.gov

Other trials for Zygomycosis

Additional recruiting or active studies for the same condition.

See all trials for Zygomycosis →

← Back to all trials